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Background: Flaxseed is a promising alternative to reduce the risk of diseases associated with body
weight excess because it is rich in a-linolenic acid, lignans, and dietary ﬁber. Flaxseed (Linum
usitatissimum) can be found in brown and golden varieties; however, questions have arisen as to
whether the variety may inﬂuence the health effects.
Objective: The objective of this study was to compare the effects of brown and golden ﬂaxseeds on
lipid proﬁle, glycemia, blood pressure, inﬂammatory status,body weight, and body composition in
overweight adolescents.
Methods: Seventy-ﬁve overweight adolescents (33 boys, 42 girls; age 13.7 ! 2.1 y), from Alegre–ES,
Brazil, were randomized to one of the three groups (n ¼ 25) on a parallel, single-blind clinical trial.
They received 28 g/d of brown ﬂaxseed (BF), golden ﬂaxseed (GF), or the equivalent amount of
wheat bran (Control, CG) in different preparations at school from Monday to Friday for 11 wk.
Blood pressure, anthropometric evaluation, and the analyses of blood total cholesterol, lipopro-
teins, glucose, and inﬂammatory markers were performed at the beginning and at the end of the
intervention. The data were analyzed by ANCOVA at 5% signiﬁcance.
Results: The groups who consumed brown and golden ﬂaxseed showed signiﬁcant reduction in
diastolic blood pressure. Brown and golden ﬂaxseed did not differentially affect plasma lipid re-
sponses, plasma glucose and inﬂammatory proﬁle, although all groups (BF, GF, and CG) showed
increased levels of TNF-a.
Conclusions: The adolescents consumed about half the daily amount provided, which may not have
been sufﬁcient to exert the health beneﬁts of ﬂaxseed reported in the literature, concerning the
lipid proﬁle, inﬂammation biomarkers and body composition.
 2015 Elsevier Inc. All rights reserved.Introduction
The prevalence of overweight and obesity is increasing
among children and adolescents and may lead to patterns of
obesity in adulthood. The 2008 to 2009 Family Budget Survey in
Brazil [1] revealed that over a period of 34 y, the percentage ofception and design of the
n of data, drafting, critical
manuscript. The authors
lare no conﬂict of interest.
6.
osta).
ll rights reserved.overweight children and adolescent boys has increased
approximately 6-fold from 3.7% to 21.7%, and the percentage of
overweight girls increased nearly 3-fold from 7.6% to 19%.
Additionally, obesity increased in the same period from 0.4% to
5.9% among the boys and from 0.7% to 4.0% among the girls.
Bodyweight excess is a global epidemic and an important risk
factor for noncommunicable diseases (NCD) with high morbidity
andmortality in the overall population [2,3]. Therefore, the focus
of prevention, diagnosis, and treatment of obesity has shifted to
childhood and adolescence.
The association between NCD and obesity is largely because
of the endocrine activity of fatty tissue, i.e., the ability of fatty
tissue to secrete adipokines that are directly or indirectly
A. M. Machado et al. / Nutrition 31 (2015) 90–96 91associated with the inﬂammatory and metabolic disorders.
These processes contribute to the development of NCD, such as
dyslipidemia, arterial hypertension, insulin resistance, type 2
diabetes mellitus, and atherosclerosis, and represent a relevant
link between adiposity and its complications [4,5].
The subclinical chronic inﬂammation associated with obesity
induces an increase in other inﬂammatory biomarkers derived
from hepatocytes, which play a relevant role in increasing the
risk of cardiovascular diseases (CVD) [5,6], which are the main
cause of mortality worldwide [7]. Dietary strategies to increase
the consumption of u-3 fatty acids are useful to reduce the risk
of CVD. To this regard, ﬂaxseed, besides its high content of the
u-3 fatty acid, a-linolenic acid (ALA), provides other bioactive
compounds such as phytoestrogens, soluble ﬁber, minerals, and
plant proteins that might contribute to the reduction of CVD
risk [8,9].
Despite its high fat and calorie content, animal and human
studies show the intake of ﬂaxseed resulted in less weight gain,
and promoted weight maintenance or a tendency to lose weight.
Additionally, there was an improvement on the lipid proﬁle,
characterized by reduced levels of low-density lipoprotein (LDL-
cholesterol) and triacylglycerol (TAG) and an increase in the u-3
fatty acids in the plasma and adipose tissue [9–14]. Wu et al. [15]
showed that ﬂaxseed supplementation (30 g/d) for 12 wk as an
adjunct intervention to healthy lifestyle counseling reduced
central obesity, weight, waist circumference, serum glucose, total
cholesterol, LDL, ApoB, ApoE cholesterol, and blood pressure.
Their study suggested ﬂaxseed could improve central obesity on
the management of metabolic syndrome in adults. Data from
Couto andWichmann [16] indicated that 2 mo of treatment with
10 and 20 g/d of ﬂaxseed reduced BMI and waist circumference
and improved lipid proﬁle in overweight woman aged over 19 y.
It is not known, however, if ﬂaxseed could beneﬁt younger
population groups, such as adolescents, by reducing the risk of
CVD associated with excess body weight in their adulthood.
The two well-known varieties of ﬂaxseed, golden and brown,
are rich sources of lignans, ﬁber, and u-3 fatty acids, although
some differences in their chemical composition have been re-
ported. For instance, Epaminondas et al. [17] found a lower
amount of ﬁber and higher amount of soluble carbohydrates in
the golden than in the brown variety, but no differences con-
cerning lipids and proteins. Sargi et al. [18] evaluated the anti-
oxidant capacity and chemical composition in seeds rich in
u-3 and observed that golden ﬂaxseed had higher levels
of u-3 and -6, while brown ﬂaxseed showed higher antioxidant
capacity.
To our knowledge, no study to date has compared the
metabolic effects of the intake of brown and golden ﬂaxseed in
humans. Most studies reported in the literature studied the
golden variety, and few have studied brown ﬂaxseed, which is
grown in Brazil at a more affordable price. Therefore, the
objective of this study was to compare the effects of brown and
golden ﬂaxseeds on lipid proﬁle, glycemia, blood pressure, in-
ﬂammatory status, body weight, and body composition in
overweight adolescents.Materials and methods
Experimental design
The study consisted of a parallel, single-blind clinical trial. A completely
randomized design was used to distribute the participants among the three
groups: Brown ﬂaxseed group (BF) (n¼ 25; 13 girls and 12 boys), golden ﬂaxseed
group (GF) (n¼ 25; 12 girls and 13 boys), and control group (CG) (n¼ 25; 14 girls
and 11 boys). Groups BF and GF received brown or golden ﬂaxseed, respectively,in various culinary forms, and the control CG group was given wheat bran to
substitute the ﬂaxseed in the same culinary forms, for 11 wk. All groups were
instructed to maintain their usual physical activities and food intake.
Population
At the beginning of the 2012 academic year (February/March) all 137 ado-
lescents of the two largest public schools of Alegre County, Espirito Santo, Brazil,
were evaluated for weight, height, and BMI. The overweight adolescents
answered a questionnaire and were asked to sign a free consent form together
with their parents.
Seventy-ﬁve volunteers of both sexes (25 per experimental group) were
recruited for the study, based on the sample size calculation, performed using the
program BioEstat 5.0 [19], taking body weight as the main variable [10], with 90%
statistical power and 5% signiﬁcance level.
The adolescents were classiﬁed as overweight based on their body mass
index (BMI) relative to age (BMI/A> z-score þ 1 and  z-score þ2). Participants
who were using medication that could interfere with the study, such as nutra-
ceutical, cholesterol-lowering or appetite-suppressing drug, and long-term
antibiotic treatment within the last 6 mo were excluded from the study. Other
exclusion criteria were nutritional disorders, allergy or intolerance to ﬂaxseed,
and diabetes.
Ethical approval
The study was conducted according to the guidelines laid down in the Declara-
tion of Helsinki and all procedures involving human subjects were approved by
the Human Research Ethics Committee of the Center for Health Science of the
Federal University of Espirito Santo (UFES, Brazil, Protocol 207/11, October 28,
2011). Written informed consent was obtained from all subjects and their parents
or guardians.
Tested products
Both ﬂaxseed varieties (Linum usitatissimum) and the wheat bran were
purchased from the Cerealista S~ao Jose, S~ao Paulo, Brazil.
The ﬂaxseed grains were ground in a domestic blender and the ﬂour was
mixed to the ingredients. The wheat bran was not processed. The portions pro-
vided daily to adolescents contained 28 g of ﬂaxseed (golden or brown) while the
amount of wheat bran varied according with the preparation, to approximate the
amount of total dietary ﬁber preparations of the control group and groups of
ﬂaxseed (Table 1). The test and control recipes consisted of six different types of
snacks: butter cookies, cereal bars, coconut cookies, cakes, baked stuffed pastries,
and kibbeh (fried minced meatball mixed with coarse wheat). The snacks were
offered alternately during the intervention period.
The products were prepared 3 times per wk (Mondays, Wednesdays, and
Fridays) in the Diet Technique Laboratory, Center of Agriculture Sciences, Federal
University of Espirito Santo (CCA-UFES) and distributed to the participants at
school during break. The participants were instructed to consume the full portion
and to return the eventual leftovers. The leftovers were identiﬁed and taken to
the Diet Technique Laboratory to be weighed, and the quantities actually
consumed were recorded in speciﬁc spreadsheets for subsequent calculation of
the amount of consumed ﬂaxseed and wheat bran.
Data on food consumption at the beginning and end of the study were
evaluated by the 24-h dietary recall, with the aid of photographic album for three
non-consecutive days, one of them referring to the weekend. Calculating the
composition of nutrients in the food anamnesis was performed using the analysis
program AVANUTRI diets. The intake of u-6 and 3 fatty acids was calculated
using the Brazilian Table of Food Composition [20] and Table of Food Composi-
tion: Nutritional support for reference [21].
Anthropometric assessment and body composition
All of the assessments were performed at the schools. The chronologic age of
the participants was calculated based on their birth date and the date of
assessment.
The participants were weighed in a bipolar bioimpedance scale, Tanita Iron
Man Inner Scan Body Composition Monitor (Arlington Heights, IL, USA), with a
150-kg capacity and a 100-g precision. The height was measured with a
millimeter-scale portable vertical stadiometer (Alturaexata, Belo Horizonte,
MG, Brazil), with a maximum limit of 2.13 m and a precision of 1.0 mm. The
measurements were performed according to the recommendations of the World
Health Organization [2] and used to calculate the BMI of the participants, which
relates the bodyweight (kg) to the height (m) squared. The BMI was assessed and
classiﬁed using the World Health Organization curves [22].
The waist circumference (WC) was measured using an inelastic, non-
extensible tape measure with a precision of 1.0 mm (TBW Brazil, S~ao Paulo, SP,
Brazil). The measurement was performed 3 times, and the average was recorded.
When the difference between the results was>1 cm, an additional measurement
Table 1
Composition of the provided food preparations
Preparations Calories (kcal) PTN (g) LIP (g) CHO (g) Fiber (g)
FS CT FS CT FS CT FS CT FS CT
Coconut cookies 420.37 385.66 6.02 6.34 21.27 16.63 53.35 60.35 13.45 13.59
Cereal bars 379.58 281.54 6.87 7.38 20.43 14.75 46.31 40.30 10.58 10.92
Cake 464.57 461.54 9.93 11.88 23.53 20.13 56.63 68.04 10.06 10.06
Kibbeh 293.47 266.18 17.19 19.86 13.59 10.95 26.78 29.48 23.32 23.32
Baked stuffed pastries 429.23 338.99 5.58 13.07 19.12 19.31 55.97 58.29 10.91 10.91
Butter cookies 431.99 403.75 5.32 5.18 25.20 22.03 70.87 73.19 10.60 10.91
CHO, carbohydrate; CT, control (wheat bran); FS, ﬂaxseed (brown or golden); LIP, lipids; PTN, protein
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WC was measured at the midpoint between the iliac crest and last rib [23] to
calculate the waist-hip ratio (WHR).
The body fat percentage was obtained by means of a bipolar bioimpedance
scale, the Tanita Iron Man Inner Scan Body Composition Monitor [24].
Blood pressure
The arterial pressure (AP) was measured every 15 d using a sphygmoma-
nometer (BD, adult medium size) and stethoscope (BD, model Duo Sonic) ac-
cording to the recommendations in “The Fourth Report on the Diagnosis,
Evaluation, and Treatment of High Blood Pressure in Children and Adolescents” of
the U.S. Department of Health and Human Services [25]. The AP was measured 3
times, and the average of the last 2 readings was recorded.
Biochemical tests
The participants were instructed to fast for 12 h before blood sampling,
which was performed at the schools by a biochemist at baseline and after
intervention. Disposable syringes, needles, and tubes were used to collect 10 mL
of blood. Immediately after separation, the serum and plasma samples were
frozen at -80 C for later analysis of the lipid and inﬂammatory proﬁles.
Lipid proﬁle
To analyze the lipid proﬁle, the blood samples were centrifuged at 3,500 rpm
for 15 min. Commercial kits (Labtest, Lagoa Santa, MG, Brazil) were used in the
measurement of total cholesterol (TC) (Trinder, enzymatic-colorimetric assay),
high-density lipoprotein (HDL-cholesterol) (precipitation with phosphotungstic
acid and magnesium chloride), and TAG (Trinder, enzymatic-colorimetric assay).
Low-density lipoprotein (LDL-cholesterol) was estimated based on themethod of
Friedwall [26]. The TC/HDL-cholesterol and LDL/HDL-cholesterol ratios were also
calculated.
Plasma glucose
Blood samples were centrifuged at 2,500 rpm for 15min to obtain the plasma
for glucose analysis. Commercial kits (Labtest, Lagoa Santa, MG. Brazil) were
used in the measurement of plasma glucose.
Inﬂammatory markers
The CRP analysis was based on quantitative immunoturbidimetry (with a
Bioclin kit for real-time measurement of CRP). The patients with CRP levels
above 10 mg/mL were excluded from the study because such values are sug-
gestive of active inﬂammation or infection [27].
Interferon-gamma (IFN-g), TNF-a, interleukin (IL) 1 beta (IL-1 b), IL-6, IL-10,
and adiponectin (Milliplex, Millipore Corp, St Charles, MO, USA, Cat. HCYTO-
MAG and HADK1 MAG-61 K) were analyzed at the Genesis Institute of Scientiﬁc
Analyses, S~ao Paulo, SP, Brazil.
The inﬂammatory analyses were performed in 38 participants who
consumed more than the median ﬂaxseed amount (13 g/d).
Statistical analysis
The variables were subjected to descriptive analysis. In the case of the
quantitative variables, the mean and standard deviation were calculated. The
inter- and intragroup homogeneity of variance were tested by Levene’s test,
assuming equal variances as P values 0.05. The data were tested for normality
using the Kolmogorov-Smirnov test. When the assumption of normality of the
data was rejected, the variable was transformed by logarithmic function. For the
remaining normality violation supposition, the coefﬁcient of symmetry wasdetermined, assuming as symmetrical the variables whose Skewness values
ranged betweenþ1 and -1. Data were analyzed by univariate covariance analysis
(ANCOVA) adjusted for sex for comparison between groups and ANCOVA for
repeated measures adjusted by sex for comparisonwithin the group, followed by
Bonforroni’s test when required. The level of statistical signiﬁcance was estab-
lished as P < 0.05. The data were analyzed using SPSS, version 19 (IBM SPSS
Statistics Base, DMSS, S~ao Paulo, SP, Brazil).Results
No variable violated the assumption of equal variances for
intra- and intergroups and all variables showed the distribution
pattern of normality.
The average intake of brown ﬂaxseed was 14.4  5.5 g/d,
golden ﬂaxseed 14.5  5.6 g/d, and wheat bran 14.1  3.4 g/d,
which represents about half the daily amount provided.Participants
Among the 75 initial volunteers, 61 completed the study (CG
n ¼ 21; BF n ¼ 20; GF n ¼ 20), with dropouts arising from the
difﬁculty of ingestion of products offered (n ¼ 12), change of
school (n ¼ 1), and health reasons not related to the project (n ¼
1). The average age was 13.7  2.1 y.Anthropometry, body composition, and blood pressure
No signiﬁcant differences (P > 0.05) were observed in the
groups relative to the anthropometric parameters and body
composition. A signiﬁcant increase in body weight in BF (59.28
 12.03 to 61.25  12.57; P < 0.001) and GF (63.84  10.31 to
64.88  10.09; P ¼ 0.01) groups was observed, but without a
signiﬁcant difference in the BMI. The GF group also showed a
signiﬁcant increase in the percentage of body fat (24.97  7.16
to 25.59  6.84; P ¼ 0.006). The waist circumference and sys-
tolic pressure did not differ in any group. There was a signiﬁ-
cant reduction in the diastolic pressure of the BF and GF group
(76.18  8.06 to 69.71  10.68 mmHg; P ¼ 0.007 and 78.03 
10.36 to 70.53  6.21; P ¼ 0.013, respectively). WHR was
reduced in CG group (0.47  0.03 to 0.45  0.03; P ¼ 0.016)
(Table 2).Lipid proﬁle
There was no signiﬁcant difference in lipid proﬁle either at
baseline or after the study between groups (P > 0.05) (Table 3).
Although not statistically signiﬁcant, the TAG levels exhibited a
7.3% reduction in the BF group, and the HDL levels increased by
2.4% and 1.7% in groups BF and GF, respectively. The ratios
TC/HDL-cholesterol and LDL/HDL-cholesterol did not exhibit a
statistical change in any group.
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No signiﬁcant changes (P > 0.05) were observed in blood
glucose levels between groups and intragroup (Table 3).Inﬂammatory and anti-inﬂammatory biomarkers
The groups did not differ regarding the values of TNF-a, IL-
10, CRP, IL-6, IFN-g, and adiponectin (P > 0.05). All of the
groups exhibited a signiﬁcant increase in the level of TNF-a at
the end of the study and IL-1 bwas not expressed by any group
(Table 4).Discussion
Epidemiologic and clinical evidence supports the beneﬁcial
effect of ﬂaxseed consumption on lipid, inﬂammatory, and
anthropometric proﬁles in adult individuals, especially for in-
takes above 20 g/d. To our knowledge, no study has been done
to test the beneﬁcial effects of ﬂaxseed on younger individuals,
such as overweight adolescents.
According to the FDA [28], 2 oz (56 g) of nuts per day should
be added to the diet to promote health beneﬁts. The quantity of
ﬂaxseed offered in the present studywas half of that used in the
study reported by Mc Kiernan et al. [29], which showed the
beneﬁts of a daily portion of 56 g peanuts per 1 mo in adults.
The amount of ﬂaxseed offered in the present study was aimed
at better compliance by the adolescents, and to compensate for
the lower daily dose offered, the intervention period was
extended to 2mo. The consumption of ﬂaxseed andwheat bran,
however, was approximately half of the initially proposed daily
dose (28 g), which may have inﬂuenced the results. The
behavior of the volunteers may have been affected by other
reasons not related to the preparations, such as the stigmati-
zation of products designed for overweight adolescents.
No signiﬁcant changes in lipid proﬁle, blood glucose and
inﬂammatory proﬁle were observed in the present study. A
reduction in diastolic blood pressure occurred in adolescents
who consumed either variety of ﬂaxseed compared with the
CG. However, the GF group showed increased body weight,
coupled with the increase in the percentage of body fat. There
was an unexpected increase in TNF-a levels in all groups.
Adolescence is characterized by growth spurts and modiﬁ-
cations on body composition, and associated with sexual
maturation. Therefore, the observed increase in height in all
groups was expected. The participants of both the BF and GF
groups exhibited a signiﬁcant increase in body weight without
a signiﬁcant change in BMI. Adolescents who consumed golden
ﬂaxseed also showed a signiﬁcant increase in body fat. The
height and weight increased and changes in body composition
were likely to happen, because these physiological changes are
inherent to adolescence and, therefore, may not be associated
with the consumption of ﬂaxseed.
Pineda et al. [30] assessed the effect of an intake of 30 g/d of
ground ﬂaxseed on body weight, BMI, and the dietary intake of
10 individuals with excess weight over 8 wk. The changes in the
body fat percentage were widely variable (40% of participants
gained weight, of these, 50% reduced fat percentage, 25%
showed no change in the percentage and 25% had combined
weight and fat gain). The authors suggested that the con-
sumption of ﬂaxseed without a reduction in energy intake or an
increase in physical activity does not lead to weight loss in in-
dividuals with excess weight.
Table 3
Biochemical characteristics of the participants at the beginning and at the end of the study*
Variables Control group (n ¼ 21) Brown ﬂaxseed (n ¼ 20) Golden ﬂaxseed (n ¼ 20) P
Baseline End (week 11) P Baseline End (week 11) P Baseline End (week 11) Py
Adjusted
mean  SD
Adjusted
mean  SD
Adjusted
mean  SD
Adjusted
mean  SD
Adjusted
mean  SD
Adjusted
mean  SD
TAG (mmol/L)z 0.80  0.40 0.97  0.46 0.090 0.84  0.30 0.78  0.36 0.504 0.78  0.44 0.86  0.43 0.367 0.353
TC (mmol/L)z 3.40  0.41 3.71  0.81 0.102 3.37  0.74 3.73  1.06 0.082 3.20  0.67 3.47  1.07 0.299 0.645
HDL (mmol/L)z 1.10  0.25 1.10  0.38 0.955 1.08  0.22 1.11  0.42 0.827 0.98  0.20 0.96  0.28 0.812 0.541
LDL (mmol/L)z 1.93  0.48 2.17  0.92 0.237 1.90  0.62 2.26  1.01 0.094 1.87  0.56 2.12  1.11 0.366 0.853
Glucose (mmol/L) 4.37  0.94 4.09  0.47 0.211 4.67  0.83 4.19  0.57 0.053 4.50  0.83 4.17  0.78 0.192 0.879
TC/HDLz 3.28  1.01 3.94  2.22 0.196 3.21  0.88 3.72  1.43 0.205 3.40  0.93 3.88  1.49 0.232 0.926
LDL/HDLz 1.93  0.95 2.46  1.92 0.254 1.83  0.76 2.36  1.32 0.144 2.02  0.76 2.44  1.47 0.259 0.984
HDL, high-density lipoprotein; LDL, low-density lipoprotein; LDL/HDL, low-density lipoprotein/high-density lipoprotein ratio; TAG, triacylglycerol; TC, total cholesterol;
TC/HDL, cholesterol/high-density lipoprotein ratio
* Data are given as adjusted mean and SD per treatment group unless noted otherwise. Labeled means in a row with superscripts with a *Statistically different, P <
0.05, based on Bonferroni test.
y P values for differences between treatments. Values are shown for the treatment effect analyzed using a mixed model analysis of covariance.
z Group GF (n ¼ 19): for the other participants was not possible to obtain these measures
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alteration in the present study. Flaxseed contains 40% lipids
(70–73% is polyunsaturated). ALA represents more than 50% of
such fat, with a concentration 3 times higher than that of the u-6
fatty acids. For this reason, ﬂaxseed is considered one of the
richest sources of plant u-3 fatty acids, and interest in studies of
the possible functional effects of ﬂaxseed is increasing [31], as
ALA is believed to improve lipid proﬁle by several mechanisms
[11,32–35].
A meta-analysis of 28 studies [9] showed that the intake of 20
to 50 g/d of ﬂaxseed signiﬁcantly lowered total cholesterol
around 0.1 to 0.2 mmol/L (3.87 to 7.73 mg/dL) and LDL from 0.08
to 0.16 mmol/L (3.09 to 6.18 mg/dL) in moderately hypercho-
lesterolemic individuals. The effects of ﬂaxseed on improving
lipid proﬁle were shown in hypercholesterolemic individuals
[14] and in adults following a low-fat diet [36,37]. It seems that
the effects of ﬂaxseed on lipid metabolism are dependent on the
baseline lipid proﬁle as well as on the lipid content of the diet. At
the beginning of this study, participants were normolipidemic,
and they pursued their habitual diet throughout the intervention
period, which may explain the lack of results with the use of
ﬂaxseed in this population.
Further more, the consumption of approximately 14 g/d of
ﬂaxseed was not sufﬁcient to promote glucose reduction. TheTable 4
Pro- and anti-inﬂammatory characteristics of the participants at the beginning and a
Variables Control group (n ¼ 12) Brown ﬂaxseed (n
Baseline End (week 11) P Baseline En
Adjusted
mean  SD
Adjusted
mean  SD
Adjusted
mean  SD
A
m
CRP (mg/dL)z 0.04  0.09 0.09  0.22 0.249 0.08  0.09 0
TNF-a (pg/mL)x 2.79  1.57 5.11  2.43 0.002* 5.32  1.45 6
IFN-g (pg/mL){ 0.45  0.24 0.52  0.14 0.341 1.45  2.42 1
IL-6 (pg/mL) 2.19  1.92 1.86  1.07 0.187 3.31  0.90 2
IL-10 (pg/mL) 1.26  0.32 1.33  0.58 0.696 4.50  7.56 4
Adiponectin
(mg/mL)
14.35  6.13 17.85  10.18 0.089 12.92  8.49 13
CRP, C-reactive protein; IFN-g, interferon-gamma; IL-10, interleukin 10; IL-1b, interle
factor-alpha
* Data are given as mean or median and SD or IQR per treatment group unless not
different, P < 0.05, based on Bonferroni test.
y P values for differences between treatments. Values are shown for the treatment
z Group BF (n ¼ 10): exclusion of samples with CRP above 10 mg/dL.
x Group CG (n ¼ 10) and GF (n ¼ 8): to other participants the values found for the
{ Group CG (n ¼ 11) and BF (n ¼ 8): to other participants the values found for theeffect of ﬂaxseed on glucose metabolism is uncertain and re-
quires further investigation [38–40].
Several studies with animals and humans have demonstrated
beneﬁcial effects of ﬂaxseed and its components on arterial
pressure [12,41–43]. In participants who consumed brown and
golden ﬂaxseed in the present study, diastolic blood pressure
exhibited a signiﬁcant reduction of 6.47 and 7.5 mm Hg,
respectively, but there was no signiﬁcant effect on the systolic
pressure. The mechanism of action of ﬂaxseed and its compo-
nents regarding arterial pressure is not well understood. It is
believed that the intake of ﬂaxseed is associated with increased
endothelial synthesis of nitric oxide, a vasodilator [44]. Reduced
stimulation of nitric oxide production enhances the contractile
activity of angiotensin II, which subsequently results in vaso-
constriction and reduced vascular contractility and eventually
leads to nephropathy, retinopathy, neuropathy, and hyperten-
sion [45,46].
The beneﬁcial effect of polyunsaturated fatty acids (PUFAs),
especially the u-3 fatty acids on the anti-inﬂammatory, antith-
rombogenic, and immunomodulatory properties of PUFAs
mostly dates from the 1970s [47]. The u-3 and u-6 PUFAs are
metabolically different and exhibit opposite physiological ac-
tions. Although theu-3 series has suppressive effects, such as the
inhibition of lymphocyte proliferation, the production oft the end of the study*
¼ 12) Golden ﬂaxseed (n ¼ 14) Py
d (week 11) P Baseline End (week 11) P
djusted
ean  SD
Adjusted
mean  SD
Adjusted
mean  SD
.14  0.24 0.361 0.10  0.20 0.20  0.22 0.126 0.430
.58  1.90 0.009* 4.04  1.33 5.44  1.94 0.006* 0.240
.00  0.85 0.594 0.50  0.27 0.96  1.23 0.372 0.512
.04  0.93 0.814 3.17  3.04 5.14  6.99 0.575 0.405
.10  8.01 0.364 1.69  1.26 1.91  1.07 0.631 0.309
.07  8.78 0.909 11.98  5.00 11.07  3.96 0.418 0.141
ukin-1 beta; IL-6, interleukin-6; IQR, interquartile range; TNF-a, tumor necrosis
ed otherwise. Labeled means in a row with superscripts with a * are statistically
effect analyzed using a mixed model analysis of covariance.
se parameters were below the detection limit.
se parameters were below the detection limit.
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and the activation of natural killer (NK) cells, the u-6 series
shows both stimulant and inhibitory effects in the immune
response. Consequently, nutritional balance is required to ensure
the homeostasis and normal development of the organism [48,
49]. In addition to its high content of PUFAs, ﬂaxseed is rich in
lignans (secoisolariciresinol diglucoside - SDG), which show
anti-inﬂammatory properties that might be associated with the
reduction of oxidative stress [50,51].
Regarding the inﬂammatory proﬁle, the present study did not
show signiﬁcant changes in the levels of CRP, IL-6, or IFN-g
induced by brown or golden ﬂaxseed intake. IL-1 b was not
expressed by any group at any investigated time-point. Addi-
tionally, the levels of IL-10 and adiponectin, anti-inﬂammatory
mediators, did not change at the end of the study. Similarly,
other authors did not ﬁnd any effect on the inﬂammatory proﬁle
in animal and human studies [37,38,52–54].
Faintuch et al. [55], however, observed a signiﬁcant reduction
in the levels of CRP after the intake of 30 g/d of ﬂaxseed sup-
plements over 2 wk by morbidly obese men and women ages 18
to 65 y old. Beneﬁcial effects were also found after dietary sup-
plementation with ﬂaxseed lignans [52]; they showed a signiﬁ-
cant difference of approximately 15% in the CRP levels of healthy
women supplemented with lignans (SDG at 500 mg/d) com-
pared with the group that was given a placebo. Another study
conducted with obese women found signiﬁcant reductions in
inﬂammatory markers (CRP and IL-6) after supplementation
with SDG at 600 mg/d over 3 mo [56].
In contrast to the above-mentioned studies, which reported
positive or no effect of ﬂaxseed on the inﬂammatory proﬁle, the
present study found a signiﬁcant increase in the levels of TNF-a.
However, this result is most likely not to be related to the use of
ﬂaxseed or its components because this increasewas observed in
all groups, including the CG.
In conclusion, the consumption of brown and golden ﬂaxseed
signiﬁcantly reduced diastolic blood pressure in overweight
adolescents, compared with the control group, and no difference
was observed between the two varieties. The low compliance to
the food intake protocol may be one of the reasons why no other
physiological effect was observed. Strategies to improve the
consumption of ﬂaxseed should be considered in further in-
vestigations to elucidate the beneﬁcial effects of ﬂaxseed in
overweight and dyslipidemic adolescents in the context of a
caloric-restricted diet.
Conclusions
In conclusion, the consumption of brown and golden ﬂaxseed
signiﬁcantly reduced diastolic blood pressure in overweight
adolescents, compared with the control group, and no difference
was observed between the two varieties. The low compliance to
the food intake protocol may be one of the reasons why no other
physiological effect was observed. Strategies to improve the
consumption of ﬂaxseed should be considered in further in-
vestigations to elucidate the beneﬁcial effects of ﬂaxseed in
overweight and dyslipidemic adolescents in the context of a
caloric-restricted diet.
The low adherence of adolescents regarding the consumption
of ﬂaxseed products, resulting in low intake of ﬂaxseed and
wheat bran (half the provided amount), is one of the main lim-
itations of this study. Many inﬂammatory proﬁle variables did
not reach the detection limit, which also limited our conclusions
concerning the effects of ﬂaxseed on immune response. The
volunteers were young, overweight, and presented their levels oflipids, glucose and blood pressure mostly within normal values.
The beneﬁts of ﬂaxseed are more likely to be shown in adult
obese individuals with more severe dyslipidemia.Acknowledgments
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